Proactive Investors - Run By Investors For Investors

LeanLife Health taps Chris Nichols as operations advisor

Nichols formerly managed dozens of capital projects from design through to completion and boasts of experience with Coca Cola and Molson Coors
omega 3 gel caps
Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives

LeanLife Health Inc (CSE:LLP) announced Wednesday that it has hired Chris Nichols as operations advisor to consult on the design of the company’s production facility.

Nichols, who will assist the new operations manager Glenn Nichols, boasts over 25 years of operations experience with companies such as Coca Cola and Molson Coors.

READ: LeanLife Health continues in-house testing of its omega-3 products, reprices warrants

Using Six Sigma tools and training, Nichols specialized in process improvement and optimization in his previous positions, leveraging the moves into multiple millions of annualized cost savings. Nichols, who holds a science degree from Simon Fraser University, formerly managed dozens of capital projects from design through to completion. 

Headquartered in Vancouver, Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives. The long-lasting shelf life of the flaxseed oil produced by LeanLife's patented method makes it an ideal fortified food ingredient. It has been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

READ: LeanLife Health bolsters team with new operations manager

The global Omega-3 market hit US$33 billion in 2016 and is expected to reach more than $57 billion by 2025, according to a report by Grand View research. Studies have since shown that Omega-3 fatty acids keep nerve cells functioning at optimal speed.

LeanLife shares held steady at C$0.04 in morning trade on Wednesday.

Contact Ellen Kelleher at [email protected]

View full LLP profile View Profile

LeanLife Health Timeline

Newswire
February 07 2019

Related Articles

Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use